Citizens JMP raised the firm’s price target on Artivion (AORT) to $53 from $47 and keeps an Outperform rating on the shares. Artivion’s Q3 results reflected a beat and raise, as well as positive incremental product and clinical updates, the analyst tells investors in a research note. The firm continues to be impressed by Artivion’s strong fundamentals, dependable base business, complementary advanced stent graft division, and notable EBITDA growth and margin profile.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AORT:
- Artivion’s Strong Q3 Performance and Growth Prospects Justify Buy Rating
- Artivion Inc. Reports Strong Q3 2025 Financial Results
- Artivion reports Q3 non-GAAP EPS 16c, consensus 15c
- Artivion raises FY25 revenue view to $439M-$445M from $435M-$443M
- Artivion announces treatment of first patient in ARTIZEN pivotal trial